Image Place holder

Farhad Khimani, MD


Specialty: Medical Oncology
Program: Blood and Marrow Transplant and Cellular Immunotherapy

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Hodgkin Lymphoma , Leukemia , Myelodysplastic Syndromes (MDS) , Non-Hodgkin Lymphoma

Dr. Khimani’s Clinical interest is specifically in Blood and Marrow transplantation. His area of focus is Lymphoma and Acute Leukemia.  He routinely takes care of patients with Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Acute Myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome etc. who require autologous or allogeneic hematopoietic stem cell transplantation as a curative treatment option for their malignancy.

Education & Training

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology
  • Internal Medicine

Fellowship:

  • West Virginia University - Hematology/Oncology
  • Moffitt Cancer Center - Blood and Marrow Transplantation

Residency:

  • West Virginia University - Internal Medicine

Medical School:

  • Aga Khan University Medical College - MD
Participating Trials

CLINICAL TRIAL 17263
Phase I Trial of ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
Condition: Malignant Hematology
Intervention: FK506 (Tacrolimus); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus
Open

CLINICAL TRIAL 18331
Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes
Condition: Malignant Hematology
Intervention:
Open

CLINICAL TRIAL 18783
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); FK506 (Tacrolimus); Melphalan; Pacritinib; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Tacrolimus; busulfan; fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19089
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
Condition: Malignant Hematology
Intervention: Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19203
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Condition: Malignant Hematology
Intervention: Cellcept (Mycophenolate Mofetil); Hydroxyurea (Droxia); MESNA; Mycophenolate Mofetil; Radiotherapy; Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus; Thiotepa (Thioplex); Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19201
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML
Condition: Malignant Hematology
Intervention: Placebo; gilteritinib
Open

CLINICAL TRIAL 18329
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); KTE-C19; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19627
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Condition: Malignant Hematology
Intervention: Rituxan (rituximab); Rituxan Hycela; rituximab
Open

CLINICAL TRIAL 19800
A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Condition: Malignant Hematology
Intervention: KD025
Open

CLINICAL TRIAL 19721
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-12)
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19961
A Phase 1B/2 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Eq001 In Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Condition: Malignant Hematology
Intervention: EQ001; Placebo
Open

CLINICAL TRIAL 19829
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate the Safety and Clinical Activity of PBCAR0191 in Subjects with Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Condition: Malignant Hematology
Intervention: PBCAR0191; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19960
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-Cd19 Allogeneic Car T Cell Therapy in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma
Condition: Malignant Hematology
Intervention: ALLO-501; ALLO-647; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19070
Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel or the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: Axicabtagene Ciloleucel (KTE-C19); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab; Varlilumab
Open

CLINICAL TRIAL 19719
A Phase Ib, Multicenter Study To Determine The Safety And Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma
Condition: Malignant Hematology
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib); Tisagenlecleucel
Open

CLINICAL TRIAL 19720
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) In Adult Patients with Refractory or Relapsed Follicular Lymphoma
Condition: Malignant Hematology
Intervention: Tisagenlecleucel
Open

CLINICAL TRIAL 20036
Phase II trial of APR-246 in combination with azacitidine as maintenance therapy for TP53 mutated AML or MDS following allogeneic stem cell transplant
Condition: Malignant Hematology
Intervention: APR-246; azacitidine (5-azacitidine)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Jun. Pubmedid: 31175906.
  • Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan;12(1):6. Pubmedid: 30630534. Pmcid: PMC6329157.
  • Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar;103(3):531-539. Pubmedid: 29242294. Pmcid: PMC5830373.
  • Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2018 Jun;54(1):85-89. Pubmedid: 29895929.
  • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e35-e39. Pubmedid: 29126867.
  • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb;24(2):400-405. Pubmedid: 29032266.
  • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul;52(7):1003-1009. Pubmedid: 28368376.
  • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec;22(12):2201-2207. Pubmedid: 27660169.
  • Khimani F, Curley B, Almubarak M. Survey of Patients Referred to a University Cancer Center for Benign Hematology: Quality Measures and Patient Understanding. J Oncol Pract. 2015 Jan;11(1):26-29. Pubmedid: 25406129.
  • Khimani F, Hoban C, Williams V, Mavromatis B, Auber ML, Abraham J, Higa GM. Efficacy of solubilized vemurafenib administered via nasogastric tube. Future Oncol. 2014 Feb;10(2):165-170. Pubmedid: 24490602.
  • Palla AR, Khimani F, Craig MD. Warm Autoimmune Hemolytic Anemia with a Direct Antiglobulin Test Positive for C3 and Negative for IgG: A Case Study and Analytical Literature Review of Incidence and Severity. Clin Med Insights Case Rep. 2013 May;6:57-60. Pubmedid: 23645992. Pmcid: PMC3623608.
  • Kamal A, Khimani F, Raza R, Zafar S, Bandeali S, Jan S. Characteristics of TIA and its management in a tertiary care hospital in Pakistan. BMC Res Notes. 2008 Aug;1:73. Pubmedid: 18755043. Pmcid: PMC2546420.
  • Majeed K, Mahmud H, Khawaja HR, Mansoor S, Masood S, Khimani F. Complementary and Alternative Medicine: Perceptions of Medical Students from Pakistan. Med Educ Online. 2007 Dec;12(1):4469. Pubmedid: 28253096.